Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2009-016720-31
    Sponsor's Protocol Code Number:250901
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2010-04-20
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2009-016720-31
    A.3Full title of the trial
    BAX 326 (Factor IX recombinante): Estudio en fase I/III prospectivo, controlado, multicéntrico
    que evalúa la farmacocinética, eficacia, seguridad e inmunogenicidad en pacientes con hemofilia
    B grave (nivel de FIX<1) o moderadamente grave (nivel de FIX< o = 2%) tratados previamente.
    BAX326 (recombinant Factor IX): A Phase 1/3 Prospective, Controlled, Multicenter Study
    Evaluatin Pharmacokinetics, Efficacy, Safety, Immunogenicity in Previously Treated Patients
    with Severe (FIX level < 1%) or Moderately Severe (FIX level < or = 2%) Hemophilia B.
    A.3.2Name or abbreviated title of the trial where available
    BAX 326
    A.4.1Sponsor's protocol code number250901
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBaxter Innovations GmbH
    B.1.3.4CountryAustria
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNA
    D.3.2Product code BAX326
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNonacog alfa
    D.3.9.1CAS number 181054-95-5
    D.3.9.2Current sponsor codeBAX 326
    D.3.9.3Other descriptive nameFactor IX de coagulación recombinante;human factor IX protein (IUPAC)
    D.3.10 Strength
    D.3.10.1Concentration unit IU international unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeFactor IX humano de coagulación (rADN) producido por tecnología de ADN recombinante en células mamarias derivadas de células de ovario de hámster chino (CHO). DCI: Nonacog alfa
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNA
    D.3.2Product code BAX326
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNonacog alfa
    D.3.9.1CAS number 181054-95-5
    D.3.9.2Current sponsor codeBAX 326
    D.3.9.3Other descriptive nameFactor IX de coagulación recombinante; human factor IX protein (IUPAC)
    D.3.10 Strength
    D.3.10.1Concentration unit IU international unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeFactor IX humano de coagulación (rADN) producido por tecnología de ADN recombinante en células mamarias derivadas de células de ovario de hámster chino (CHO). DCI: Nonacog alfa
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name BENEFIX 500 UI, polvo y disolvente para solución inyectable
    D.2.1.1.2Name of the Marketing Authorisation holderWYETH EUROPE LTD.
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namebenefix
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNONACOG ALFA
    D.3.9.3Other descriptive nameNONACOG ALFA
    D.3.10 Strength
    D.3.10.1Concentration unit IU/kg international unit(s)/kilogram
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeFactor IX de coagulación recombinante
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Pacientes con hemofilia B grave (nivel de FIX < 1%) o moderadamente grave (nivel de FIX < o = 2%)
    tratados previamente.
    To assess BAX 326 pharmacokinetic (PK) parameters and to determine bioequivalence with BeneFIX, to evaluate its hemostatic efficacy, safety, immunogenicity, and changes in health-related quality of life (HR QoL).
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 11
    E.1.2Level LLT
    E.1.2Classification code 10018939
    E.1.2Term Hemofilia B (Factor IX)
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Evaluar los parámetros farmacocinéticos (FC) de BAX 326 y determinar la bioequivalencia con
    BeneFIX, evaluar su eficacia hemostática, seguridad, inmunogenicidad, y los cambios en la calidad de
    vida relacionada con la salud (CVRS).
    E.2.2Secondary objectives of the trial
    -Comparar los parámetros FC de BAX 326 con los de BeneFIX. -Controlar la recuperación creciente
    (RC) de BAX 326 a lo largo del tiempo. -Evaluar la eficacia hemostática de BAX 326 en el manejo y
    prevención de los episodios hemorrágicos agudos durante un período de 6 meses. -Evaluar la
    seguridad en función de los acontecimientos adversos (AA) relacionados con BAX 326, la
    inmunogenicidad durante un mínimo de 50 días de exposición (DE), la trombogenicidad durante las
    partes FC, así como los cambios clínicamente significativos en los parámetros de laboratorio de rutina
    (hematología/bioquímica clínica) y constantes vitales. -Evaluar los cambios en la CVRS y la
    utilización de recursos sanitarios.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    -Paciente de entre 12 y 65 años de edad en el momento de la selección. -Paciente y/o representante legal
    ha(n) firmado el consentimiento informado. -Paciente con hemofilia B grave (nivel de FIX < 1%) o
    moderadamente grave (nivel de FIX <= 2%) (en base al ensayo de tiempo de tromboplastina parcial
    activado (TTPa) de una etapa), según el examen de la selección en el laboratorio central. -Paciente
    previamente tratado con concentrados de FIX recombinante y/o derivado de plasma durante al menos
    150 días DE (en base a la historia clínica del paciente). -Si un paciente no presenta una historia clínica
    verificable y documentada de 150 DE, éste podrá entrar en el estudio si 1) presenta 100 # 150 DE a
    cualquier producto de FIX (concentrados de FIX recombinante o derivado de plasma, crioprecipitado, o
    plasma fresco congelado) no completamente documentados, y 2) ha participado en el protocolo de
    Immunine 050901 y ha acumulado ya sea un mínimo de 50 DE a Immunine o un total de por lo menos
    150 DE a un concentrado de FIX recombinante y/o derivado de plasma antes de entrar en el estudio
    -Paciente sin evidencia de antecedentes de inhibidores del FIX (en base a la historia clínica del
    paciente). Si no se encuentra disponible una historia clínica verificable y documentada, el paciente
    podrá entrar en el estudio si ha participado en el Estudio 050901 durante por lo menos 50 DE a
    Immunine antes de su inclusión. -Paciente dispuesto a recibir tratamiento profiláctico durante un
    período de 6 meses. -Paciente inmunocompetente según lo evidencia un cifra de CD4 >= 200
    células/mm3. -Paciente seronegativo al virus de inmunodeficiencia humana (VIH) o VIH+ con una
    carga viral < 200 partículas/microlitros, aproximadamente <400.000 copias/ml. -Si es mujer en edad
    fértil, la paciente presenta un test de embarazo negativo y acepta utilizar medidas anticonceptivas
    adecuadas durante el transcurso del estudio. -Paciente dispuesto a cumplir los requisitos del protocolo y
    capaz de hacerlo.
    E.4Principal exclusion criteria
    -Paciente con antecedentes de inhibidores del FIX con un valor >= 0,6 Unidades Bethesda (UB) (según
    lo determine la modificación Nijmegen del ensayo Bethesda o el ensayo empleado en el laboratorio
    local correspondiente) en cualquier momento anterior a la selección. -Paciente que presenta un inhibidor
    del FIX detectable en la selección, con un valor >= 0,6 UB según lo determine la modificación
    Nijmegen del ensayo Bethesda en el laboratorio central. -Paciente con antecedentes de reacción
    alérgica, por ej. anafilaxia, tras la exposición al/a los concentrado(s) de FIX. -Paciente con
    hipersensibilidad conocida a las proteínas de hámster o Furina-r. -Paciente con evidencia de patología
    trombótica, fibrinólisis o coagulación intravascular diseminada (CIV) actual o reciente. -Paciente con
    función renal anormal (creatinina sérica > 1,5 veces el límite superior del intervalo normal). -Paciente
    con enfermedad hepática grave crónica según lo evidencian, entre otros, cualquiera de los siguientes:
    Razón internacional normalizada (RIN) que excede el límite superior del intervalo normal,
    hipoalbuminemia, hipertensión portal, que incluye presencia de esplenomegalia sin otra explicación y
    antecedentes de varices esofágicas. -Paciente con enfermedad hepática activa con niveles de alanina
    aminotransferasa (ALT) o aspartato aminotransferasa (AST) >= 2 veces el límite superior del intervalo
    normal. -Paciente con diagnóstico de un defecto hemostático hereditario o adquirido distinto a la
    hemofilia B. -Cifra de plaquetas del paciente < 100.000/ml. -Paciente con una patología médica,
    psiquiátrica o cognitiva significativa, o uso de drogas recreativas/alcohol que a criterio del investigador
    podría afectar la seguridad o cumplimiento del paciente. -Paciente al que actualmente se administra o
    que tiene programada la administración durante el transcurso del estudio de una medicación
    inmunomoduladora (por ej., agentes corticoesteroides a una dosis equivalente a más de 10 mg/día de
    hidrocortisona o interferón alfa;) distinta a la quimioterapia antirretroviral. -Paciente que ha participado
    en otro estudio de investigación dentro de los 30 días previos al ingreso. La participación en el estudio
    050901 con Immunine está permitida. -Paciente miembro del equipo que realiza este estudio o que se
    encuentra en relación de dependencia con uno de los miembros del equipo del estudio. Las relaciones de
    dependencia incluyen a los parientes cercanos (es decir, hijos, pareja/cónyuge, hermanos/as, padres) así
    como empleados del investigador o personal del centro que realiza el estudio.
    E.5 End points
    E.5.1Primary end point(s)
    #FC: -FC primaria: ABC0-72 h/dosis (área bajo la curva concentración plasmática # tiempo desde las 0
    hasta las 72 horas siguientes a la infusión) -FC secundaria: ABC de cero a infinito; /dosis (área bajo la
    curva de concentración plasmática/tiempo desde el momento 0 hasta el infinito), TMR (tiempo medio
    de residencia), DP (depuración), RC, T1/2 (semivida o vida media de la fase de eliminación), Vee
    (volumen de distribución en estado estacionario). -RC a lo largo del tiempo. #Eficacia hemostática
    -Tratamiento de los episodios hemorrágicos: Cantidad de infusiones por episodio hemorrágico,
    calificación de eficacia hemostática total. -Profilaxis: Tasa de hemorragias anualizada. -Consumo de
    BAX 326: Cantidad de infusiones y consumo ajustado de acuerdo al peso por mes y año; consumo
    ajustado de acuerdo al peso por episodio (profilaxis y a demanda). #Seguridad: -Desarrollo de
    anticuerpos e inhibidores anti factor IX -Desarrollo de anticuerpos contra las proteínas de ovario de
    hámster chino (CHO) y furina recombinante (Furina-r) -Aparición de reacciones alérgicas graves, por
    ej. anafilaxia -Aparición de episodios trombóticos y cambios clínicamente significativos en los
    marcadores trombogénicos durante las partes FC del estudio: Fragmento de protrombina 1.2 (F 1.2),
    trombina-antitrombina III (TAT), dímero D. -AA relacionados con el PI -Cambios clínicamente
    significativos en los parámetros de laboratorio de rutina (hematología y bioquímica clínica) y constantes
    vitales #Parámetros de la CVRS y farmacoeconómicos -Cambios en los siguientes parámetros de la
    CVRS y utilización de recursos sanitarios #Para pacientes de entre 12 y 16 años de edad -Específicos de
    la enfermedad: Haemo-QoL versión abreviada -Genéricos: PedsQL# -Utilidad sanitaria: EQ-5D
    -Evaluación general del dolor a través de una escala visual análoga (EVA) -Utilización de recursos
    sanitarios #Para pacientes a partir de los 17 años de edad: -Específicos de la enfermedad:
    Haemo-A-QoL -Genéricos: SF-36 -Utilidad sanitaria: EQ-5D -Evaluación general del dolor a través de
    una EVA -Utilización de recursos sanitarios
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Inmunogenicidad , trombogenicidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Fase I farmacocinética / fase III eficacia
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Parte 1: aleatorizado, controlado, cruzado, ciego. Partes 2 y 3: abierto, no controlado
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA20
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Según el protocolo
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2010-04-20. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    niños 12-17 años
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 30
    F.4.2.2In the whole clinical trial 60
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Después de la finalización del estudio, los sujetos pueden entrar en un estudio de continuación cubierto
    por un protocolo separado de BAX 326 hasta que el producto tenga la correspondiente autorización de
    comercialización en su país.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2010-07-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2010-06-04
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2012-05-03
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 17:57:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA